SCHEMBL25201186

SCHEMBL25201186

N#CC(C#N)=C1CCc2c(Cl)cccc21

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.54
BCHE P06276 1/20 0.37
CYP19A1 P11511 2/20 0.36
CYP11B1 P15538 2/20 0.36
CYP11B2 P19099 2/20 0.36
DYRK1A Q13627 1/20 0.33
ALDH1A1 P00352 1/20 0.33
TRPA1 O75762 1/20 0.33
NPSR1 Q6W5P4 2/20 0.32
RXFP1 Q9HBX9 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
ADRA2A P08913 1/20 0.32
CYP2D6 P10635 1/20 0.32
ADRA2B P18089 1/20 0.32
ADRA2C P18825 1/20 0.32
ADRA1D P25100 1/20 0.32
ADRA1A P35348 1/20 0.32
ADRA1B P35368 1/20 0.32
PNMT P11086 1/20 0.32
NOTUM Q6P988 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24483586 0.90 EGFR (0.44) EGFRBCHECYP19A1CYP11B1CYP11B2
SCHEMBL7049498 0.79 EGFR (0.54) EGFRDYRK1AALDH1A1NOTUM
SCHEMBL30067519 0.79 EGFR (0.54) EGFRCYP19A1CYP11B1CYP11B2ALDH1A1
SCHEMBL24483083 0.79 EGFR (0.54) EGFRCYP19A1CYP11B1CYP11B2ALDH1A1
SCHEMBL7049632 0.72 EGFR (0.33) EGFRDYRK1AALDH1A1TRPA1
SCHEMBL24483759 0.71 ALDH1A1 (0.48) EGFRCYP19A1CYP11B1CYP11B2ALDH1A1
SCHEMBL6286885 0.71 EGFR (0.53) EGFRCYP19A1ALDH1A1NPSR1MAPT
SCHEMBL30067338 0.71 EGFR (0.55) EGFRCYP19A1ALDH1A1MAPT
SCHEMBL255282 0.71 EGFR (0.55) EGFRCYP19A1ALDH1A1MAPT
SCHEMBL31061166 0.70 EGFR (1.00) EGFRADRA2AADRA2BADRA2CADRA1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136582-A1 SELECT KRAS G12C INHIBITORS AND USES THEREOF 1200 PHARMA LLC (US) 2025-05-01 US disclosed
CN-119156383-A Selective KRAS G12C inhibitors and uses thereof 1200药业有限责任公司 2024-12-17 CN disclosed
EP-4430035-A1 SELECT KRAS G12C INHIBITORS AND USES THEREOF 1200 Pharma LLC (US) 2024-09-18 EP disclosed
WO-2023086383-A1 SELECT KRAS G12C INHIBITORS AND USES THEREOF 1200 PHARMA LLC (US) 2023-05-19 WO disclosed
WO-2023086383-A1 SELECT KRAS G12C INHIBITORS AND USES THEREOF 1200 PHARMA LLC (US) 2023-05-19 WO disclosed
WO-2022240971-A2 KRAS G12D INHIBITORS AND USES THEREOF 1200 PHARMA LLC (US) 2022-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136582-A1 SELECT KRAS G12C INHIBITORS AND USES THEREOF KRAS, NRAS, HRAS EGFR 69/4885BCHE 4830/4885CYP19A1 3046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.